Brinckerhoff Quoted on Amgen v. Sandoz Decision

23 July 2015 Pharmaceutical Executive News

Pharmaceutical Executive

Partner Courtenay Brinckerhoff was quoted in Pharmaceutical Executive’s article, “Biosimilars: The Next Chapter,” on July 23, 2015. The article discussed the U.S. Court of Appeals for the Federal Circuit’s decision in Amgen v. Sandoz and its impact on the biosimilar sector of the pharmaceutical industry. Brinckerhoff outlined the case milestones and said, “Sandoz first gave notice of its plans to commercially market Zarxio before the FDA had approved its application. Amgen argued that notice was ineffective because the statute requires notice of a ‘licensed’ product, which only can be given once the product is approved. The district court agreed with Sandoz on this issue, but the Federal Circuit agreed with Amgen.”

Related Services


RCE PTA Carve-Out Resumes After Interference
18 September 2019
The Ninth Circuit Expected to Rule that Doctors Can Be Wrong in the Winter v. Gardens False Claims Act Case
18 September 2019
Legal News: Government Enforcement Defense & Investigations
Upcoming Webinar: Maximizing Solar Tax Credits - Navigating the Start of Construction Rules (Part 1)
17 September 2019
Renewable Energy Outlook
When Birds Finally Find a Nest
17 September 2019
Dashboard Insights
Lacktman, Ferrante Cited in mHealth Intelligence About Ryan Haight Act
19 September 2019
mHealth Intelligence
Tinnen Discusses How Viewpoint Diversity Helps Businesses Thrive
18 September 2019
Vernaglia Comments on AHA v Azar Decision
18 September 2019
MedPage Today
Lach Comments on Launch of New Group
16 September 2019
BizTimes Milwaukee
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
BRG Healthcare Leadership Conference
06 December 2019
Washington, D.C.
CTeL Telehealth Fall Summit 2019
04-06 December 2019
Washington, D.C.